Author(s): Rajeshwar Kamal Kant Arya, Neeraj Kumar Sethiya, Dheeraj Bisht, Mohmmad Rashid, Deepak Kumar, Anita Singh, Rupa Gupta, Vijay Singh Rana

Email(s): dheeraj.bisht729@gmail.com

DOI: 10.52711/0974-360X.2023.00153   

Address: Rajeshwar Kamal Kant Arya1, Neeraj Kumar Sethiya2, Dheeraj Bisht1*, Mohmmad Rashid3, Deepak Kumar4, Anita Singh1, Rupa Gupta5, Vijay Singh Rana2
1Department of Pharmaceutical Sciences, Sir J. C. Bose Technical Campus Bhimtal, Kumaun University, Nainital, Uttarakhand, India - 263136.
2Faculty of Pharmacy, DIT University, Dehradun, Uttarakhand, India - 248009.
3Department of Pharmaceutical Chemistry and Pharmacognosy, College of Dentistry and Pharmacy, Buraydah Colleges, Al-Qassim, Saudi Arabia - 31717.
4Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, 173229, India
5Department of Pharmacy, School of Health Sciences, Sushant University, Gurugram, Haryana, 122003, India.
*Corresponding Author

Published In:   Volume - 16,      Issue - 2,     Year - 2023


ABSTRACT:
This review article covers the proposed synthetic and natural medicines, and their contribution in aspects of chemistry and metabolism for the management of COVID-19, which is still lacking in many published current studies. Most of the current studies were focused on physiology, epidemiology, and management of COVID-19. However, only a few of such studies mainly focussed on the chemistry of medicine in the management of the disease. In this contest, both natural and synthetic medicines, their synthesis and metabolism are highlighted in the current article. Currently, the entire world is struggling with the COVID-19 pandemic that has disturbed every aspect of life, caused by a newly discovered virus strain named severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). The outbreak continues to evolve, several research activities have been continuously carried out for understanding the origin, functions, treatments, and preventions of novel coronavirus (nCoV) infections such as SARS-CoV-2, SARS-CoV-1. There a lot of lines of treatment are being used all over the world but still, the perfect line of treatment for COVID-19 is not available. Various kinds of antiviral, anti-malarial, ACE inhibitors, and immunosuppressant drugs are being trialled worldwide for the management of COVID-19. A synthetic drug such as antimalarial drug (Hydroxychloroquine\Chloroquine), antiviral drug (Favipiravir, Remdesivir, Oseltamivir, EIDD-1931, Lopinavir, and Ritonavir), angiotensin-converting enzyme inhibitors/ angiotensin-receptor blockers (Captopril and Losartan), and immunosuppressant/arthritic drugs (Actemra, Baricitinib, Ruxolitinib, and Kevzara) for the management therapy for COVID-19 herewith complied to describe the chemical features and proposed metabolism process. Further, both chemistry and metabolism of proposed natural drug therapy such as quercetin, patchouli alcohol, baicalin, glycyrrhizic acid, and andrographolide for the management of COVID-19 infection are also included.


Cite this article:
Rajeshwar Kamal Kant Arya, Neeraj Kumar Sethiya, Dheeraj Bisht, Mohmmad Rashid, Deepak Kumar, Anita Singh, Rupa Gupta, Vijay Singh Rana. An Overview on Chemical Features and Metabolism of Synthetic and Natural Product-Based Medicine for Combating COVID-19. Research Journal of Pharmacy and Technology 2023; 16(2):908-6. doi: 10.52711/0974-360X.2023.00153

Cite(Electronic):
Rajeshwar Kamal Kant Arya, Neeraj Kumar Sethiya, Dheeraj Bisht, Mohmmad Rashid, Deepak Kumar, Anita Singh, Rupa Gupta, Vijay Singh Rana. An Overview on Chemical Features and Metabolism of Synthetic and Natural Product-Based Medicine for Combating COVID-19. Research Journal of Pharmacy and Technology 2023; 16(2):908-6. doi: 10.52711/0974-360X.2023.00153   Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-2-72


REFERENCES:
1.    Shereen MA, Khan S, Kazmi A, Bashir N and Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human corona viruses. Journal of Advanced Research. 2020; 24: 91-98.
2.    Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003; 362(9393): 1353-1358.
3.    Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID- 19): the epidemic and the challenges. International Journal of Antimicrobial Agents 2020; 55(3): 105924.
4.    World Health Organization. Laboratory testing for coronavirus disease (‎COVID-19) ‎ in suspected human cases: interim guidance, 19 March 2020. World Health Organization. https://apps.who.int/ iris/handle/10665/331501. License: CC BY-NC-SA 3.0 IGO.
5.    Buchholz U, Müller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, Bonin F, Drosten C, Schweiger B, Wolff T, Muth D, Meyer B, Buda S, Krause G, Schaade L, Haas W. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Eurosurveillance 2013; 18: 20406.
6.    Centre for Disease Prevention and Control. Update: Severe Respiratory Illness Associated with a Novel Coronavirus—Worldwide, 2012-2013. Annals of Emergency Medicine 2013; 62(3): 269-270.
7.    Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R, Price N, Newsholme W, Drosten C, Fouchier RA, Zambon M. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Eurosurveillance 2012; 17: 20290.
8.    Al-Osail AM, Al-Wazzah MJ. The history and epidemiology of Middle East respiratory syndrome corona virus. Multidisciplinary Respiratory Medicine 2017; 12: 20.
9.    Kahn JS, McIntosh K. History and Recent Advances in Corona virus Discovery, The Paediatric Infectious Disease Journal 2005; 24(11): S223-S227.
10.    Acter T, Uddinm N, Das J, Akhter A, Choudhury TR. Evolution of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) as corona virus disease 2019 (COVID-19) Pandemic: A global health emergency. Science of the Total Environment 2020; 730: 4-6.
11.    Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, Liang W, Zheng H, Wan K, Liu Q, Cui B, Xu Y, Zhang E, Wang H, Ye J, Li G, Li M, Cui Z, Qi X, Chen K, Du L, Gao K, Zhao Y, Zou X, Feng Y, Gao Y, Hai R, Yu D, Guan Y, Xu J. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms Journal of Virology 2005; 79(18): 11892-11900.
12.    Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018; 23(2): 130-137.
13.    Hunter JC, Nguyen D, Aden B, Bandar ZA, Dhaheri WA, Elkheir KA, Khudair A, Mulla MA, Saleh FE, Imambaccus H, Kaabi NA, Sheikh FA, Sasse J, Turner A, Wareth LA, Weber S, Ameri AA, Amer WA, Alami NN, Bunga S, Haynes LM, Hall AJ, Kallen AJ, Kuhar D, Pham H, Pringle K, Tong S, Whitaker BL, Gerber SI, Al-Hosani FI. Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi. Emerging Infectious Diseases. 2016; 22(4): 647-656.
14.    van-Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, Wit E, Munster VJ. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine. 2020; 382(16): 1564-1567.
15.    Warren-Gash C, Fragaszy E, Hayward AC. Hand hygiene to reduce community transmission of influenza and acute respiratory tract infection: a systematic review. Influenza and Other Respiratory Viruses. 2013; 7(5): 738-749.
16.    Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-513.
17.    Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International Journal of Cardiology 2020; 309: 70-77.
18.    Okusaga O, Yolken RH, Langenberg P, Lapidus M, Arling TA, Dickerson FB, Scrandis DA, Severance E, Cabassa JA, Balis T, Postolache TT. Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. Journal of Affective Disorders. 2011; 130(1-2): 220-225.
19.    Akhtar MJ. COVID19 inhibitors: A prospective therapeutics. Bioorganic Chemistry 2020; 101: 104027.
20.    Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nature Nanotechnology 2020; 15(4): 247-249.
21.    Pooladanda V, Thatikonda S, Godugu C. The current understanding and potential therapeutic options to combat COVID-19. Life Science. 2020; 254: 117765.
22.    Lim H, Im J, Cho J, Bae K, Klein TA, Yeom J, Kim T, Choi J, Jang I, Park J. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrobial Agents and Chemotherapy. 2009; 53(4): 1468-1475.
23.    Li H, Yang L, Liu F, Ma X, He P, Tang W, Tong X, Zuo J. Overview of therapeutic drug research for COVID-19 in China. Acta Pharmacologica Sinica. 2020; 41(9): 1133-1140.
24.    Bray PG, Hawley SR, Ward SA. 4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake. Molecular Pharmacology. 1996; 50(6): 1551-1558.
25.    Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research. 2009; 82(3): 95-102.
26.    Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020; 19(3): 149-150.
27.    Guo Q, Xu M, Guo S, Zhu F, Xie Y, Shen J. The complete synthesis of favipiravir from 2-aminopyrazine. Chemical Papers. 2019; 73: 1043-1051.
28.    Venkatasubbaiah M, Reddy D, Satyanarayana SV. Literature-based review of the drugs used for the treatment of COVID-19. Current Medicine Research and Practice. 2020; 10(3): 100-109.
29.    Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine. 2003; 163(14): 1667-1672.
30.    Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clinical Infectious Diseases. 2011; 53(3): 277-279.
31.    Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy. 1998; 42(12): 3218-3224.
32.    Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Therapeutics and Clinical Risk Management. 2008; 4(5): 1023-1033.
33.    McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research. 2020; 157: 104859.
34.    Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, Xiaoneng M, Jian W, Wang Y, Peng P, Chen X, Hong W, Xiao G, Liu J, Zhang L, Hu F, Li F, Zhang F, Deng X, Li L. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Medicine (New York, N.Y.). 2020; 1(1): 105-113.
35.    Ghosh AK, Bilcer G, Schiltz G. Syntheses of FDA Approved HIV Protease Inhibitors, Synthesis (Stuttg). 2001; 2001(15): 2203-2229.
36.    Mehta N, Amirshahi MM, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. The American Journal of Emergency Medicine. 2020; 38: 1488-1493.
37.    Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2, Nature Medicine 2020; 26: 450-452.
38.    Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MS. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19, ACS Central Science. 2020; 6(5): 672-683.
39.    Amirian ES, Levy JK. Current knowledge about the anti-virals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses, One Health 2020; 9: 100128.
40.    Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, Bluemling GR, Lockwood MA, Sheahan TP, Sims AC, Natchus MG, Saindane M, Kolykhalov AA, Painter GR, Baric RS, Denison MR. Small-Molecule Antiviral β-d- N 4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. Journal of Virology 2019; 93(24): e01348-19.
41.    Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-COV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science Translational Medicine. 2020; 12(541): eabb5883.
42.    Toots M, Yoon J, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine. 2019; 11(515): eaax5866.
43.    Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circulation Research. 2020; 126(10): 1456-1474.
44.    Huang F, Li Y, Leung EL, Liu X, Liu K, Wang Q, Lan Y, Li X, Yu H, Cui L, Luo H, Luo L. A review of therapeutic agents and Chinese herbal medicines against SARSCOV- 2 (COVID-19). Pharmacological Research. 2020; 158: 104929.
45.    Bisht D, Kumar D, Kumar D, Dua K, Chellappan DK. Phytochemistry and pharmacological activity of the genus Artemisia. Arch Pharm Res. 2021; 44(5): 439-474.
46.    Lau JT, Leung PC, Wong EL, Fong C, Cheng KF. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms and improve quality of life: a prospective cohort study. Journal of Alternative and Complementary Medicine. 2005; 11(1): 49-55.
47.    Andrea GD. Quercetin: A flavone with multifaceted therapeutic applications, Fitoterapia. 2015; 106: 256-271.
48.    Paemanee A, Hitakarun A, Wintachai P, Roytrakul S, Smith DR, A proteomic analysis of the anti-dengue virus activity of andrographolide, Biomedicine and Pharmacotherapy. 2019; 109: 322-332.
49.    Bisht D, Rashid M, Aryaa RKK, Kumar D, Chaudhary SK, Rana VS, Sethiya NK. Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: potential pharmacological applications with mechanistic insight. Phytomedicine Plus. 2021; 100206.
50.    Hoever G, Baltina L, Michaelis M, Kondratenko R, Baltina L. Activity of glycyrrhizic acid derivatives against SARS-coronavirus. Journal of Medicinal Chemistry. 2015; 48(4): 1256-1259.
51.    Ahmad M, Rashid M, Ali B, Khan MS, Akhtar N, Khan MF, Panda BP. Immobilization of β-glucuronidase: biocatalysis of glycyrrhizin to 18β-glycyrrhetinic acid and in-silico lead finding, Journal of Chinese Pharmaceutical Sciences. 2020; 29(5): 333-340.
52.    Deng YF, Aluko RE, Jin Q, Zhang Y, Yuan LJ. Inhibitory activities of Baicalin against renin and angiotensin-converting enzyme, Pharmaceutical Biology. 2012; 50: 401-406.
53.    Li YC, Peng SZ, Chen HM, Zhang FX. Oral administration of patchouli alcohol isolated from Pogostemonis Herba augments protection against influenza viral infection in mice. International Immunopharmacology. 2012; 12(1): 294-301.
54.    Maggin S, Wenzlaff IS, Hornig D. Essential Role of Vitamin C and Zinc in Child Immunity and Health. Journal of International Medical Research. 2010; 38(2): 386-414.
55.    Li Y, Schellhorn HE. New developments and novel therapeutic perspectives for vitamin C. Journal of Nutrition. 2007; 137: 2171-2184.
56.    Wintergerst ES, Maggini S, Hornig DH. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Annals of Nutrition and Metabolism. 2006; 50: 85-94.
57.    Wu X, Zhou H, Wu X, Huang W, Jia B. Strategies for qualified triage stations and fever clinics during the outbreak of Covid 19 in the county hospitals of Western Chongqing. Journal of Hospital Infection. 2020; 105: 1-2.
58.    Zhang J, Zhou LM, Yang Y, Peng W. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respiratory Medicine. 2020; 8(3): e11-e12.
59.    Liao XL, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Medicine, 2020; 46(2): 357-360.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available